HPV vaccine efficacy in preventing persistent cervical HPV infection: A systematic review and meta-analysis

Vaccine

Volumn 25, Issue 50, 2007, Pages 8352-8358

  La Torre, G ^a   de Waure, C ^a   Chiaradia, G ^a   Mannocci, A ^a   Ricciardi, W ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Efficacy; HPV vaccine; Meta analysis

Indexed keywords

PLACEBO; WART VIRUS VACCINE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; DISEASE TRANSMISSION; DRUG EFFICACY; GENITAL TRACT INFECTION; HEALTH CARE SYSTEM; HEALTH PROGRAM; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFECTION RISK; META ANALYSIS; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SYSTEMATIC REVIEW; UTERINE CERVICITIS; WART VIRUS;

ADOLESCENT; ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; UTERINE CERVICAL NEOPLASMS;

EID: 36249026545     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.09.027     Document Type: Review

References (35)

1. World Health Organization. Viral cancer. Human papillomavirus. Available from http://www.who.int/vaccine_research/diseases/viral_cancers/en/index3.html [accessed on February 9, 2007].
2. Dunne E.F., and Markowitz L.E. Genital human papillomavirus infection. Clin Inf Dis 43 5 (2006) 624-629
3. Clifford G.M., Gallus S., Herrero R., Muñoz N., Snijders P.J.F., Vaccarella S., et al. Worldwide distribution of human papillomavirus types in citologically normal women in the international agency for research on cancer HPV prevalence surveys: a pooled analysis. Lancet 366 9490 (2005) 991-999
4. Ronco G., Ghisetti V., Segnan N., Snijders P.J., Gillio-Tos A., Meijer C.J., et al. Prevalence of human papillomavirus infection in women in Turin, Italy. Eur J Cancer 41 2 (2005) 297-305
5. Centurioni M.G., Puppo A., Merlo D.F., Pasciucco G., Cusimano E.R., Sirito R., et al. Prevalence of human papillomavirus cervical infection in an Italian asymptomatic population. BMC Infect Dis 5 (2005) 77
6. Garden J.M., O'Banion M.K., Shelnitz L.S., Pinski K.S., Bakus A.D., Reichmann M.E., et al. Papillomavirus in the vapor of carbon dioxide laser-treated verrucae. JAMA 259 8 (1988) 1199-1202
7. Moy R.L., Eliezri Y.D., Nuovo G.J., Zitelli J.A., Bennett R.G., and Silverstein S. Human papillomavirus type 16 DNA in periungual squamous cell carcinomas. JAMA 261 18 (1989) 2669-2673
8. Baseman J.G., and Koutsky L.A. The epidemiology of human papillomavirus infections. J Clin Virol 32 Suppl 1 (2005) S16-S24
9. Kashima H.K., Shah F., Lyles A., Glackin R., Muhammad N., Turner L., et al. A comparison of risk factors in juvenile-onset and adult-onset recurrent respiratory papillomatosis. Laryngoscope 102 1 (1992) 9-13
10. Koutsky L.A., Galloway D.A., and Holmes K.K. Epidemiology of genital human papillomavirus infection. Epidemiol Rev 10 (1988) 122-163
11. Melchers W., de Mare S., Kuitert E., Galama J., Walboomers J., and van den Brule A.J. Human papillomavirus and cutaneous warts in meat handlers. J Clin Microbiol 31 9 (1993) 2547-2549
12. Schiffman M., and Castle P.E. Human papillomavirus: epidemiology and public health. Arch Pathol Lab Med 127 8 (2003) 930-934
13. Walboomers J.M.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189 1 (1999) 12-19
14. IARC. Human papillomaviruses. In: IARC monographs on the evaluation of carcinogenic risks to humans. 64th ed. Lyon: IARC Press; 1995.
15. Cuzick J., Clavel C., Petry K.U., Meijer C.J., Hoyer H., Ratnam S., et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 119 5 (2006) 1095-1105
16. International Agency for Research on Cancer (IARC). IARC handbook of cancer prevention. Cervical cancer screening vol. 10 (2005), IARC Press, Lyon, France
17. Greer C.E., Wheeler C.M., Ladner M.B., Beutner K., Coyne M.Y., Liang H., et al. Human papillomavirus (HPV) type distribution and serological response to HPV type 6 virus-like particles in patients with genital warts. J Clin Microbiol 33 8 (1995) 2058-2063
18. Ault K.A. Vaccines for the prevention of human papillomavirus and associated gynecologic diseases: a review. Obstet Gynecol Surv 61 6 Suppl 1 (2006) S26-S31
19. Jadad A.R., Moore A., Carroll D., Jenkinson C., Reynolds D.J., Gavaghan D.J., et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Control Clin Trials 17 1 (1996) 1-12
20. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Ault K.A., Giuliano A.R., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6 5 (2005) 271-278
21. Villa L.L., Ault K.A., Giuliano A.R., Costa R.L., Petta C.A., Andrade R.P., et al. Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18. Vaccine 24 27-28 (2006) 5571-5583
22. Villa L.L., Costa R.L., Petta C.A., Andrade R.P., Paavonen J., Iversen O.E., et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 95 11 (2006) 1459-1466
23. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 364 9447 (2004) 1757-1765
24. Harper D.M., Franco E.L., Wheeler C.M., Moscicki A.B., Romanowski B., Roteli-Martins C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 9518 (2006) 1247-1255
25. Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Barr E., Alvarez F.B., et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 347 21 (2002) 1645-1651
26. Mao C., Koutsky L.A., Ault K.A., Wheeler C.M., Brown D.R., Wiley D.J., et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 107 1 (2006) 18-27
27. Brown D.R., Fife K.H., Wheeler C.M., Koutsky L.A., Lupinacci L.M., Railkar R., et al. Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine. Vaccine 22 21-22 (2004) 2936-2942
28. Paavonen J., Jenkins D., Bosch F.X., Naud P., Salmerón J., Wheeler C.M., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 369 9580 (2007) 2161-2170
29. Centers for Disease Control and Prevention. ACIP provisional recommendations for the use of quadrivalent HPV vaccine; 2006. Available from http://www.cdc.gov/nip/recs/provisional_recs/hpv.pdf [accessed on February 14, 2007].
30. EMEA. Relazione di valutazione pubblica europea (EPAR). Gardasil. EMEA/H/C/703. [European public evaluation report. Gardasil. EMEA/H/C/703]. Available from http://www.emea.europa.eu/humandocs/PDFs/EPAR/gardasil/070306it1.pdf [accessed on March 05, 2007].
31. Ministero della Salute. Consiglio superiore di sanità. Sessione XLVI. Sezioni congiunte II e III. Seduta dell'11 gennaio 2007 [Ministry of Health. Higher Health Council. XLVI Session. I and II joined Sections. January 11, 2007 session].
32. Reisinger K.S., Block S.L., Lazcano-Ponce E., Samakoses R., Esser M.T., Erick J., et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J 26 3 (2007) 201-209
33. Pedersen C., Petaja T., Strauss G., Rumke H.C., Poder A., Richardus J.H., et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health 40 6 (2007) 564-571
34. American Cancer Society News Center. ACS Recommends HPV Vaccine But Cervical Cancer Screening Still Necessary. Available from: http://www.cancer.org/docroot/NWS/content/NWS_1_1x_ACS_Recommends_HPV_Vaccine.asp [accessed on 05-03-2007].
35. La Torre G., Chiaradia G., de Waure C., Mannocci A., Capri S., Bruno S., et al. Health technology assessment and vaccine: new needs and opportunities?. Ital J Public Health 4 1 (2007) 81-88